Chronic hepatitis B tests answer different questions: Is infection present? How much virus is circulating? Is liver-cell injury occurring? Has scarring developed? HBV DNA, ALT, and fibrosis findings must be interpreted together and followed over time. A reassuring result in one category cannot answer all of those questions.
After hepatitis B is identified, testing helps a clinician assess liver health, consider treatment, and monitor changes. This guide focuses on that follow-up. For a broader introduction, see Ulta’s Liver Function Tests pillar and Infectious Disease Testing pillar.
Start with the complete report, previous results, and vaccination and exposure history. The three initial screening markers have different roles:
CDC recommends the triple panel at least once for adults aged 18 and older. Ulta’s Hepatitis B Titer Test Panel includes these three markers. It does not include a viral load or fibrosis assessment. 1
| HBsAg | Total anti-HBc | Anti-HBs | Usual interpretation |
|---|---|---|---|
| Positive | Positive | Negative | Current infection; additional information distinguishes acute from chronic infection. |
| Negative | Positive | Positive | Resolved natural infection; reactivation can still occur with certain immune-suppressing treatments. |
| Negative | Negative | Positive | Consistent with vaccine immunity when the vaccination history fits. |
| Negative | Negative | Negative | Usually susceptible if there is no documented completed vaccine series; antibodies can wane after vaccination. |
| Negative | Positive | Negative | Isolated core antibody; possible explanations include past infection with waning anti-HBs, a false positive, or occult infection. Further evaluation depends on the circumstances. |
These are common patterns, not every possible combination. A result that conflicts with the clinical history may need confirmation or repeat testing. Persistence of HBsAg for at least six months establishes chronic infection, but evaluation should begin when infection is identified. There is no reason to wait six months to seek care. 2
The Hepatitis B Core IgM Antibody Test can help when recent acute infection is suspected. IgM anti-HBc can also become positive during a severe flare or reactivation of chronic hepatitis B, so it cannot establish a new infection by itself. 1
For comparisons with hepatitis A and C, read Understanding Hepatitis Testing: Key Hepatitis Tests for A, B, and C.
The Hepatitis B Virus DNA Quantitative Test measures viral DNA in blood. Often called the HBV viral load, it is usually reported in international units per milliliter, or IU/mL, and sometimes as a logarithmic value.
This quantitative assay is used to help manage established infection and assess treatment response. It is not a substitute for the initial screening panel or the confirmation process for a new diagnosis.
Read the result wording carefully:
Keep the laboratory’s detection limits, units, and comments with each result. When comparing different laboratories or methods, ask whether the results are directly comparable. A falling viral load can support a favorable treatment response, but it does not measure how much liver scarring remains. 3
HBV DNA describes the amount of circulating virus. The ALT Test measures alanine aminotransferase, an enzyme that rises with liver-cell injury. The AST Test provides additional context, although AST can also rise because of muscle injury and other causes.
Neither enzyme directly measures the liver’s remaining functional capacity or establishes a fibrosis stage. A person may have substantial viral replication with a normal ALT, or an elevated ALT for a reason other than active HBV-related injury. Interpretation requires serial results, fibrosis assessment, and clinical history. 3, 4
| Result pattern | What it may mean | What needs attention |
|---|---|---|
| High HBV DNA with normal ALT | Viral replication and measured liver injury are not moving together. | Age, fibrosis, HBeAg status, and trends still affect treatment assessment. |
| Low HBV DNA with elevated ALT | HBV alone may not explain the liver-enzyme abnormality. | Evaluate other causes of liver injury and follow the trend. |
| HBeAg negative, HBV DNA below 2,000 IU/mL, and persistently normal ALT | This can fit an inactive phase in an untreated person. | Confirm the pattern over time; ongoing monitoring remains necessary. |
| Increasing HBV DNA and ALT | Changing viral activity or a flare may be developing. | Review symptoms, medication use, adherence, and liver function promptly. |
| Undetectable HBV DNA during treatment, with HBsAg still positive | Treatment may be suppressing replication. | Continue the prescribed care plan; this does not establish cure. |
The table illustrates clinical questions, not instructions to classify disease or start medication. “Normal” ALT also depends on the threshold used: clinical guidance may use a lower limit than a laboratory’s reference interval. A clinician should explain which threshold applies. 3
The Hepatitis Be Antigen Test, or HBeAg, and Hepatitis Be Antibody Test, or anti-HBe, add information about the infection’s biological pattern. Loss of HBeAg with development of anti-HBe is called HBeAg seroconversion.
That change can be meaningful, but neither a negative HBeAg nor a positive anti-HBe guarantees that replication has stopped. Some HBV variants replicate without producing detectable HBeAg. Clinicians therefore interpret these markers alongside quantitative HBV DNA and ALT. 2
A clinician may use the following tests to assess injury, liver function, and possible complications. Several overlap with panels, so ordering every individual test is usually unnecessary.
| Test or panel | What it contributes | Important limitation |
|---|---|---|
| Hepatic Function Panel | Groups liver enzymes, bilirubin, and protein measurements for a broader review. | It does not measure HBV DNA or directly stage fibrosis. |
| Alkaline Phosphatase | Helps evaluate a possible bile-flow pattern of abnormal results. | Bone and other sources can also raise the value. |
| Bilirubin Fractionated | Separates bilirubin fractions to help investigate jaundice and abnormal bilirubin. | Elevated bilirubin has several possible causes. |
| Albumin | Helps assess protein production in the broader clinical picture. | Low albumin can also reflect inflammation, nutrition problems, or protein loss. |
| Complete Blood Count with Differential and Platelets | Includes platelet count and identifies blood-cell abnormalities. | A low platelet count has multiple causes and does not diagnose cirrhosis. |
| Platelet Count | Supplies a value used in some fibrosis calculations. | A separate count may duplicate the platelet measurement in a CBC. |
| Prothrombin Time with INR | Helps assess clotting and, when appropriate, impaired liver protein synthesis. | Anticoagulants, vitamin K status, and other conditions affect it. |
Changes in bilirubin, albumin, INR, and platelets may deserve attention even when ALT is only mildly elevated. The Complete Guide to Lab Tests and Blood Work explains how individual measurements and panels fit together.
Fibrosis is scar tissue that accumulates after liver injury. Advanced scarring can lead to cirrhosis. A current viral load or liver-enzyme result cannot reveal the full history of that injury.
Clinicians may use blood-based scores, transient elastography, other imaging findings, and occasionally liver biopsy. APRI uses AST relative to its upper reference limit and the platelet count. FIB-4 uses age, AST, ALT, and platelets. 4
Ulta’s FIB-4 Index Liver Health Evaluation — Self Calculation supplies AST, ALT, and platelet testing. It requires the person’s age for calculation and does not provide a definitive fibrosis stage.
A fibrosis score is a risk estimate. Its performance depends on the liver disease, age, and clinical setting. Do not automatically apply thresholds developed for metabolic fatty liver disease to chronic HBV. WHO’s hepatitis B guidance emphasizes APRI and transient elastography for noninvasive staging. 4
Inflammation can increase liver stiffness, and platelet abnormalities unrelated to liver disease can distort blood-based scores. A lower stiffness result after treatment may partly reflect less inflammation; it does not prove that all scarring has disappeared. 5
Not everyone with chronic hepatitis B needs antiviral medication immediately. A clinician combines viral activity, liver injury, fibrosis, and personal risk factors when considering treatment. Significant fibrosis or cirrhosis changes that assessment, even when symptoms are absent or ALT is not markedly elevated. 3, 8
Ask what finding would change your current plan: a persistent increase in HBV DNA, an ALT trend, evidence of fibrosis, or a change such as pregnancy or immune-suppressing treatment. If medication is deferred, monitoring remains part of care.
The schedule depends on disease activity, fibrosis, treatment, and changes in health. A written plan should identify which tests are due, when they should be repeated, and who will review them.
For example, AASLD’s 2025 educational guidance describes ALT and HBV DNA monitoring every three to six months during the first year for an inactive pattern, then every six to twelve months if stable. This is one clinical scenario, not a universal testing interval. 3
WHO similarly emphasizes monitoring that reflects disease stage, treatment response, adherence, and safety, with closer follow-up when the clinical situation warrants it. 5
The medication and the person’s kidney health determine the safety-testing plan. For example, tenofovir disoproxil fumarate can affect kidney function and renal tubular handling of minerals. Monitoring may include creatinine-based kidney estimates, phosphorus, and urine protein and glucose. 6
The Renal Function Panel includes kidney-related chemistry measurements, including creatinine and phosphorus. Urinalysis Complete includes urine protein and glucose measurements. These may supply parts of an individualized plan; they are not a universal requirement for every person with HBV.
Different antiviral medicines have different monitoring needs. Review new abnormalities with the prescribing clinician rather than changing the dose or stopping treatment independently.
No. An undetectable result during antiviral therapy generally indicates suppression below the assay’s detection limit. HBV can persist in liver cells, and the viral load can rebound after treatment stops.
HBsAg loss is a separate milestone. Decisions about withdrawing antiviral therapy require specialist assessment and, in selected circumstances, intensive follow-up. A single undetectable DNA result is not a reason to stop medication. 7
Other causes of liver injury may coexist with hepatitis B. Examples include metabolic dysfunction-associated steatotic liver disease, alcohol-related injury, medication or supplement effects, and other infections. Less common disorders may warrant targeted evaluation when the history and laboratory pattern support it.
The next step is to investigate the specific pattern. Provide the clinician with medication and supplement names, alcohol history, recent illnesses, and previous results. Repeating a large unrelated panel does not necessarily explain persistent ALT elevation. 3, 5
Coinfections can change liver risk and treatment decisions. The Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR connects antibody screening with RNA testing when the reflex criteria are met. Antibody alone does not establish current HCV infection.
HBV reactivation can occur during direct-acting antiviral treatment for hepatitis C, so the treatment team needs to know the HBV results. 8 HIV status also matters when selecting antiviral therapy; testing should be arranged as part of clinical evaluation. 3
Hepatitis D occurs in people with HBV infection and can cause substantial liver injury. Evaluation generally begins with total anti-HDV antibody, followed by HDV RNA testing if antibodies are positive to assess active infection. Low HBV DNA does not exclude hepatitis D. A clinician can arrange the appropriate assays. 9
Past infection matters even when HBsAg is negative. Tell the prescribing team about a positive total anti-HBc result before chemotherapy, B-cell-depleting treatment such as rituximab, or other significant immune suppression.
Depending on the drug regimen and HBV status, the plan may include preventive antiviral treatment or structured monitoring. Anti-HBs positivity does not eliminate the need to assess reactivation risk. 2, 8
CDC recommends HBsAg screening during every pregnancy. A pregnant person with a positive HBsAg result should have HBV DNA assessed and a coordinated maternal and infant prevention plan. 10
A viral load above 200,000 IU/mL is a threshold used when considering maternal antiviral prophylaxis to reduce transmission. For an infant born to an HBsAg-positive parent, maternal treatment does not replace hepatitis B vaccine and hepatitis B immune globulin at birth, completion of the vaccine series, and follow-up testing. Monitoring after delivery is also important because disease activity can change, particularly if preventive antiviral treatment ends. 8, 10
Hepatocellular carcinoma, or HCC, can occur in some people with chronic hepatitis B even without cirrhosis. A clinician assesses surveillance eligibility using factors such as cirrhosis, age, geographic or family background, family history of HCC, and coinfections.
For people who meet surveillance criteria, liver ultrasound and Alpha Fetoprotein Tumor Marker, or AFP, are commonly used every six months. AFP alone is not an adequate replacement for liver imaging. Other imaging may be needed when ultrasound cannot adequately evaluate the liver. 11
Viral suppression reduces risk but may not remove the need for surveillance. Some people should continue surveillance even after HBsAg loss. 3
Bring the complete laboratory report, including units, reference intervals, and comments. Ulta’s How to Read Lab Results cornerstone guide explains why those details matter.
Seek emergency care for new confusion, marked drowsiness, vomiting blood, black stools, or rapidly worsening illness. New jaundice, abdominal swelling, or persistent vomiting warrants prompt medical assessment. Do not wait for a scheduled monitoring blood draw when these symptoms develop. 12
Contact the treating team promptly about a reported critical laboratory result, a suspected flare, or an interruption in antiviral treatment. Symptoms and liver function can make a situation urgent even before the next HBV DNA result is available.
Start with the clinical question and the tests your treating clinician needs. Quantitative HBV DNA, liver chemistry tests, and selected safety measurements can contribute to follow-up, while fibrosis imaging and cancer surveillance require separate arrangements.
Use Ulta’s Direct Access Lab Testing cornerstone guide to understand the testing process, and coordinate results with the clinician managing your hepatitis B. Testing supports care; it does not replace examination, treatment decisions, or imaging.
This article provides general education. Your monitoring and treatment plan should reflect your medical history, results, and clinician’s assessment.
1. CDC: Clinical Testing and Diagnosis for Hepatitis B.
2. CDC: Screening and Testing for Hepatitis B Virus Infection — United States, 2023.
3. AASLD: Practical Application of HBV Guidelines, 2025 educational slide set.
4. WHO: Non-invasive assessment of liver disease stage, 2024 hepatitis B guidelines.
6. WHO: Monitoring the safety of nucleoside analogues, 2024.
7. WHO: When to stop and restart antiviral therapy, 2024.
8. CDC: Clinical Care of Hepatitis B.
10. CDC: Clinical Guidance for Perinatal Hepatitis B Testing.
11. WHO: Surveillance for hepatocellular carcinoma among people with chronic hepatitis B, 2024.
12. NIDDK: Treatment for Cirrhosis — management of complications.
Initial HBV status and conditional acute-infection evaluation
The titer panel groups the three initial screening markers. IgM anti-HBc serves a separate, conditional role when acute infection is suspected.
Viral activity and chronic monitoring
Liver health and fibrosis context
Conditional medication-safety monitoring
Coinfection evaluation
Liver-cancer surveillance adjunct
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
